Skip to main content
Fig. 1 | Trials

Fig. 1

From: Re-endothelialisation after Synergy stent and Absorb bioresorbable vascular scaffold implantation in acute myocardial infarction: COVER-AMI study

Fig. 1

Histogram distribution of the in-stent/scaffold area obstruction and comparative neointimal thickness with DES vs BVS stents. a Histogram distribution of in-stent/scaffold area obstruction (%) per cross-sectional level (420 cross-sections). Everolimus drug-eluting stents (DES) had median (interquartile range) of 6.4% (5.2–8.4%) and everolimus bioresorbable vascular scaffolds (BVS) had median of 7.9% (6.6–10.5%), p <  0.001. b Histogram distribution of neointimal thickness at strut level (3942 struts). Everolimus DES had mean neointimal thickness (± SD) of 0.046 ± 0.038 mm and everolimus BVS had mean (± SD) of 0.061 ± 0.062 mm, p <  0.001

Back to article page

Trials

ISSN: 1745-6215